Renal, Metabolic and Cardiovascular Diseases
Data update as of 31/12/2023
Area coordinators:
- Alberto Ortiz Arduán
AOrtiz@fjd.es
Consulta su CV - Carmen Gómez Guerrero
Cgomez@fjd.es
Consulta su CV - Carmen Garcés Segura
CGarces@fjd.es
Consulta su CV
This strategic area is made up of three groups and two associated groups, with strong ties between them. The Cardiology area recently established a very close relationship with the Carlos III National Center for Cardiovascular Research (CNIC), together carrying out experimental and clinical projects under a collaboration agreement.
Its objectives include:
- The common objective of the research area is to deepen the understanding of damage and repair mechanisms in reno-urological, cardiovascular, metabolic and diabetic diseases, from childhood onwards. Within this common framework, each group and subgroup focuses on certain aspects, sharing techniques and knowledge to accelerate discovery and translate advances to the clinic.
- Study the cellular and molecular mechanisms (fibrosis, immuno-inflammation, apoptosis, intracellular signalling, cytokines, renin-angiotensin system, etc.) involved in the pathogenesis of certain diseases (atherothrombosis, myocardial ischemia/reperfusion, cardiomyopathies, diabetic nephropathy, hypertension, glomerular pathology, acute renal failure, nephrotoxicity, obesity and diabetes, etc.).
- Application of different platforms and imaging techniques (proteomics, genomics, metabolomics, cardiac magnetic resonance, molecular imaging, etc.) to the identification of new molecules with diagnostic or therapeutic potential in the aforementioned pathologies.
- Discovery and preclinical development of new therapeutic approaches for clinical application in the prevention and/or treatment of these pathologies.
Furthermore, there is significant clinical activity, including observational studies and clinical trials (both industry and investigator-initiated) at this and other centers.
There are a large number of collaborations with national and international researchers, and within the center itself with the Anatomic Pathology, Haematology, Medical Oncology, Clinical Biochemistry, Infectious Diseases, Immunology, Microbiology, Rheumatology, Traumatology, Rheumatology and Bone Metabolism, Endocrinology, Digestive Surgery and Intensive Care Medicine groups.
Renal, Metabolic and Cardiovascular Diseases Area Scientific Activity
|
2023 |
Cardiology |
Nephrology and Hypertension, Vascular Pathology and Diabetes |
Lipid Pathology: Clinical and Experimental (adult and child) |
Cardiac and Vascular Surgery Associated Group |
Urology Associated Group |
TOTAL |
|
|
PROJECTS |
→EU/NIH PROJECTS |
3 |
4 |
// |
// |
// |
7 |
|
→ISCIII PROJECTS |
6 |
31 |
4 |
// |
// |
41 |
|
|
→CYBER PROJECTS |
1 |
2 |
// |
// |
// |
3 |
|
|
→MINISTERIAL PROJECTS |
1 |
6 |
// |
// |
// |
7 |
|
|
→ACM PROJECTS |
// |
2 |
// |
// |
// |
2 |
|
|
→AWARDS |
// |
// |
// |
// |
// |
// |
|
|
→UNOFFICIAL PROJECTS |
8 |
28 |
4 |
// |
6 |
46 |
|
|
→OBSERVATIONAL STUDIES |
1 |
2 |
2 |
1 |
2 |
8 |
|
|
TOTAL |
20 |
75 |
10 |
1 |
8 |
114 |
|
|
CLINICAL TRIALS |
→EARLY PHASES (I, I/II, II) |
2 |
4 |
1 |
// |
3 |
10 |
|
→LATE PHASES (II/III, III, III/IV AND IV/OTHER) |
21 |
12 |
3 |
// |
7 |
43 |
|
|
TOTAL |
23 |
16 |
4 |
// |
10 |
53 |
Renal, Metabolic and Cardiovascular Diseases Area Publications
|
2023 |
Total no. of publications |
No. of publications with IF |
Accumulated IF |
Average annual IF |
No. of journals in Q1 |
% of journals in Q1 |
No. of publications in Open Access |
No. of Clinical Practice Guidelines |
|
Cardiology |
48 |
47 |
457,1 |
9,73 |
29 |
61,70% |
33 |
5 |
|
Nephrology and Hypertension, Vascular Pathology and Diabetes |
159 |
159 |
1585,9 |
9,97 |
105 |
66,04% |
135 |
14 |
|
Lipid Pathology: Clinical and Experimental (adult and child) |
23 |
23 |
114,7 |
4,99 |
9 |
39,13% |
11 |
4 |
|
Cardiac and Vascular Surgery Associated Group |
4 |
4 |
9,7 |
2,43 |
1 |
25,00% |
4 |
0 |
|
Urology Associated Group |
13 |
13 |
38 |
2,92 |
3 |
23,08% |
7 |
1 |
|
RENAL, METABOLIC AND CARDIOVASCULAR DISEASES AREA |
247 |
246 |
2205,4 |
8,97 |
147 |
59,76% |
190 |
24 |
List of the five most relevant publications of the Renal, Metabolic and Cardiovascular Diseases Area during 2023
Global Burden of Cardiovascular Diseases and Risks, 1990-2022.
Mensah GA, Fuster V, Murray CJL, Roth GA, Global Burden of Cardiovascular Diseases and Risks Collaborators (Ortiz A).
J Am Coll Cardiol. 2023 Dec 19.82(25):2350-2473.
PMID: 38092509
FI: 24,4
A mutual regulatory loop between miR-155 and SOCS1 influences renal inflammation and diabetic kidney disease.
Prieto I, Kavanagh M, Jimenez-Castilla L, Pardines M, Lazaro I, Herrero Del Real I, Flores-Muñoz M, Egido J, Lopez-Franco O, Gomez-Guerrero C.
Mol Ther Nucleic Acids. 2023 Dec 12.34:102041.
PMID: 37842165
FI: 8,8
Regulated cell death pathways in kidney disease.
Sanz AB, Sanchez-Niño MD, Ramos AM, Ortiz A.
Nat Rev Nephrol. 2023 May.19(5):281-299.
PMID: 36959481
FI: 41,5
Paradigm Shift: Cardiovascular Health in the Elderly-Beware of the Brain.
Fuster V, Turco JV, Cortes-Canteli M.
J Am Coll Cardiol. 2023 Mar 28.81(12):1214-1215.
PMID: 36948739
FI: 24,4
Molecular basis of normal and pathological puberty: from basic mechanisms to clinical implications.
Argente J, Dunkel L, Kaiser UB, Latronico AC, Lomniczi A, Soriano-Guillén L, Tena-Sempere M.
Lancet Diabetes Endocrinol. 2023 Mar.11(3):203-216.
PMID: 36620967
FI: 44,5
Gender Perspective in Renal, Metabolic and Cardiovascular Diseases Area
The Renal, Metabolic and Cardiovascular Diseases Area is made up of a group of professionals committed to respect and equality among its team members, which seeks to promote the professional development of all its personnel without discrimination based on gender or age.
Renal, Metabolic and Cardiovascular Diseases Area Future Goals
- Improve the prognosis of renal diseases through the development of new diagnostic and risk stratification tools, and new therapeutic strategies.
- Improve the prognosis of metabolic diseases through the development of new diagnostic and risk stratification tools, and new therapeutic strategies.
- Improve the prognosis of cardiovascular diseases through the development of new diagnostic and risk stratification tools, and new therapeutic strategies.
- Implement new therapeutic and evaluation strategies for Urological Health Results.
Research Groups
- Cardiology
- Nephrology and Hypertension, Vascular Pathology and Diabetes
- Lipid Pathology: Clinical and Experimental (adult and child)
- Cardiac and Vascular Surgery Associated Group
- Urology Associated Group
